AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +62

AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?

Acquisition Earnings report AI-generated analysis

📈 AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.

💊 Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.

🧠 The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.

🤝 AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.

💰 The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.

⚠️ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.

📉 AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.

🔮 The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.

📉 Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.

🚀 The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.

Bullish Signals
  • AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
  • Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
  • The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
  • Total company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
Risk Factors
  • Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
  • The acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
  • AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Full Analysis
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings. The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase. Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.